-+ 0.00%
-+ 0.00%
-+ 0.00%

H. Lundbeck's Vyepti Wins Marketing Regulatory Nod in Japan

MT Newswires·09/16/2026 02:58:47
Listen to the news
02:58 AM EDT, 09/16/2026 (MT Newswires) -- H. Lundbeck (HLUN-A.CO) secured the marketing authorization from Japan's Ministry of Health, Labour and Welfare for its monoclonal antibody Eptinezumab, or Vyepti. The approval will allow the biopharmaceutical company to market Vyepti as a preventive treatment for migraine attacks in adults in Japan, according to a Wednesday release. The company added that the clearance was supported by the results of its phase 3 sunrise and sunset studies.